Literature DB >> 15475948

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Catherine M Shachaf1, Andrew M Kopelman, Constadina Arvanitis, Asa Karlsson, Shelly Beer, Stefanie Mandl, Michael H Bachmann, Alexander D Borowsky, Boris Ruebner, Robert D Cardiff, Qiwei Yang, J Michael Bishop, Christopher H Contag, Dean W Felsher.   

Abstract

Hepatocellular carcinoma is generally refractory to clinical treatment. Here, we report that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers. MYC inactivation resulted en masse in tumour cells differentiating into hepatocytes and biliary cells forming bile duct structures, and this was associated with rapid loss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver stem cell marker cytokeratin 19. Using in vivo bioluminescence imaging we found that many of these tumour cells remained dormant as long as MYC remain inactivated; however, MYC reactivation immediately restored their neoplastic features. Using array comparative genomic hybridization we confirmed that these dormant liver cells and the restored tumour retained the identical molecular signature and hence were clonally derived from the tumour cells. Our results show how oncogene inactivation may reverse tumorigenesis in the most clinically difficult cancers. Oncogene inactivation uncovers the pluripotent capacity of tumours to differentiate into normal cellular lineages and tissue structures, while retaining their latent potential to become cancerous, and hence existing in a state of tumour dormancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475948     DOI: 10.1038/nature03043

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  374 in total

1.  Investigating tumor perfusion and metabolism using multiple hyperpolarized (13)C compounds: HP001, pyruvate and urea.

Authors:  Cornelius von Morze; Peder E Z Larson; Simon Hu; Hikari A I Yoshihara; Robert A Bok; Andrei Goga; Jan Henrik Ardenkjaer-Larsen; Daniel B Vigneron
Journal:  Magn Reson Imaging       Date:  2011-12-12       Impact factor: 2.546

2.  Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene.

Authors:  Shashikiran Donthamsetty; Vishakha S Bhave; Corrine S Kliment; William C Bowen; Wendy M Mars; Aaron W Bell; Rachel E Stewart; Anne Orr; Chuanyue Wu; George K Michalopoulos
Journal:  Hepatology       Date:  2011-01-06       Impact factor: 17.425

3.  Targeting oncogenes.

Authors:  Laurie Goodman
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Authors:  Hongwu Zheng; Haoqiang Ying; Ruprecht Wiedemeyer; Haiyan Yan; Steven N Quayle; Elena V Ivanova; Ji-Hye Paik; Hailei Zhang; Yonghong Xiao; Samuel R Perry; Jian Hu; Anant Vinjamoori; Boyi Gan; Ergun Sahin; Milan G Chheda; Cameron Brennan; Y Alan Wang; William C Hahn; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 5.  MYC as a regulator of ribosome biogenesis and protein synthesis.

Authors:  Jan van Riggelen; Alper Yetil; Dean W Felsher
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

6.  Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Authors:  Joanne R Doherty; Chunying Yang; Kristen E N Scott; Michael D Cameron; Mohammad Fallahi; Weimin Li; Mark A Hall; Antonio L Amelio; Jitendra K Mishra; Fangzheng Li; Mariola Tortosa; Heide Marika Genau; Robert J Rounbehler; Yunqi Lu; Chi V Dang; K Ganesh Kumar; Andrew A Butler; Thomas D Bannister; Andrea T Hooper; Keziban Unsal-Kacmaz; William R Roush; John L Cleveland
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

7.  MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

Authors:  Brian J Altman; Annie L Hsieh; Arjun Sengupta; Saikumari Y Krishnanaiah; Zachary E Stine; Zandra E Walton; Arvin M Gouw; Anand Venkataraman; Bo Li; Pankuri Goraksha-Hicks; Sharon J Diskin; David I Bellovin; M Celeste Simon; Jeffrey C Rathmell; Mitchell A Lazar; John M Maris; Dean W Felsher; John B Hogenesch; Aalim M Weljie; Chi V Dang
Journal:  Cell Metab       Date:  2015-09-17       Impact factor: 27.287

8.  Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Authors:  James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

9.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

10.  Role of Myc in hepatocellular proliferation and hepatocarcinogenesis.

Authors:  Aijuan Qu; Changtao Jiang; Yan Cai; Jung-Hwan Kim; Naoki Tanaka; Jerrold M Ward; Yatrik M Shah; Frank J Gonzalez
Journal:  J Hepatol       Date:  2013-10-02       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.